HUTCHMED (China) Ltd
HKEX:13
Operating Margin
HUTCHMED (China) Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| HK |
H
|
HUTCHMED (China) Ltd
HKEX:13
|
16.6B HKD |
-20%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
685.8B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
362.5B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
196.2B CHF |
32%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
176.4B CHF |
32%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
205.6B USD |
36%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
155.9B GBP |
23%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
128.2B USD |
25%
|
HUTCHMED (China) Ltd
Glance View
HUTCHMED (China) Ltd., a hybrid of innovation and tradition, stands at the intersection of global pharmaceutical ambitions and Chinese herbal expertise. Born out of a joint venture between Hutchison Whampoa and Chi-Med, the company has steadily carved out a niche by developing a dual-pronged business model that merges cutting-edge biotechnology with traditional Chinese medicine. This hybrid approach enables HUTCHMED to leverage the best of both worlds by combining the rich pharmacological heritage of China with modern scientific research. Its pipeline includes a range of drugs aimed at treating various cancers and immunological disorders, developed through deep-pocketed collaborations and alliances with multinational corporations. Revenue streams at HUTCHMED primarily flow from drug discoveries and developments that pass through rigorous clinical trials, reaching commercialization both in China and internationally. The company invests significantly in R&D to advance its pipeline, while also generating income through strategic partnerships that involve licensing agreements and joint ventures. This allows HUTCHMED not only to mitigate risks associated with drug development but also to tap into diverse markets by navigating a multifaceted regulatory landscape. By paving the way for western pharmaceutical technologies alongside traditional medicinal insights, HUTCHMED creates a sustainable growth trajectory in an ever-evolving global healthcare market.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on HUTCHMED (China) Ltd's most recent financial statements, the company has Operating Margin of -19.8%.
You don't have any saved screeners yet